We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
- Authors
Canaud, Bernard; Mingardi, Giulio; Braun, Johann; Aljama, Pedro; Kerr, Peter G.; Locatelli, Francesco; Villa, Giuseppe; Vlem, Bruno Van; McMahon, Alan W.; Kerlöeguen, Cécile; Beyer, Ulrich
- Abstract
Background. Extending the administration interval of erythropoiesis-stimulating agents (ESAs) represents an opportunity to improve the efficiency of anaemia management in patients with chronic kidney disease (CKD). However, effective haemoglobin (Hb) maintenance can be challenging with epoetin alfa and epoetin beta administered at extended intervals. C.E.R.A., a continuous erythropoietin receptor activator, has a unique pharmacologic profile and long half-life (∼130 h), allowing administration at extended intervals. Phase III results have demonstrated that C.E.R.A. administered once every 4 weeks effectively maintains stable Hb levels in patients with CKD on dialysis.
- Subjects
HEMOGLOBINS; DIALYSIS (Chemistry); ANEMIA; BLOOD diseases; KIDNEY diseases
- Publication
Nephrology Dialysis Transplantation, 2008, Vol 23, Issue 11, p3654
- ISSN
0931-0509
- Publication type
Article
- DOI
10.1093/ndt/gfn320